Trazodone
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Desyrel)
Trazodone is an antidepressant drug that has also been marketed under the brand names Desyrel, Oleptro, and Trialodine.[1] It belongs to the serotonin modulator class of antidepressants.[1]
There is virtually no evidence for the use of Trazodone to treat ME/CFS. In 2012 Solve ME/CFS Initiative contracted Biovista to use drug models to identify existing drugs that may be worth investigating for treatment. The results suggested Trazodone was worth considering.[2]
Notable studies[edit | edit source]
- 2008, Nitric oxide modulation mediates the protective effect of trazodone in a mouse model of chronic fatigue syndrome[3]
- 2010, Trazodone for the treatment of fibromyalgia: an open-label, 12-week study[4]
- 2011, Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study[5]
Media coverage[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- ↑ 1.0 1.1 "Trazodone: MedlinePlus Drug Information". medlineplus.gov. Retrieved January 9, 2019.
- ↑ Solve ME/CFS Initiative - Results of Biovista Work Released
- ↑ Kumar, Anil; Garg, Ruchika; Kumar, Puneet (October 2008), "Nitric oxide modulation mediates the protective effect of trazodone in a mouse model of chronic fatigue syndrome", Pharmacological reports: PR, 60 (5): 664–672, ISSN 1734-1140, PMID 19066412
- ↑ Morillas-Arques, Piedad; Rodriguez-Lopez, Carmen Ma; Molina-Barea, Rocio; Rico-Villademoros, Fernando; Calandre, Elena P. (September 10, 2010), "Trazodone for the treatment of fibromyalgia: an open-label, 12-week study", BMC musculoskeletal disorders, 11: 204, doi:10.1186/1471-2474-11-204, ISSN 1471-2474, PMC 2945951, PMID 20831796
- ↑ Calandre, Elena P.; Morillas-Arques, Piedad; Molina-Barea, Rocío; Rodriguez-Lopez, Carmen M.; Rico-Villademoros, Fernando (May 16, 2011), "Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study", BMC musculoskeletal disorders, 12: 95, doi:10.1186/1471-2474-12-95, ISSN 1471-2474, PMC 3112435, PMID 21575194
